{"id":"bicalutamide-oral-product","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Hot flashes"},{"rate":"30-50%","effect":"Impotence"},{"rate":"20-40%","effect":"Breast tenderness"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to androgen receptors in cells, thereby blocking the effects of androgens such as testosterone and dihydrotestosterone. This can help slow the growth of prostate cancer cells.","oneSentence":"Bicalutamide is a nonsteroidal antiandrogen that inhibits the action of androgens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:56.612Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic prostate cancer"},{"name":"Early stage prostate cancer"}]},"trialDetails":[{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT03070886","phase":"PHASE2, PHASE3","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-04-05","conditions":"Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":612},{"nctId":"NCT05746806","phase":"NA","title":"Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-29","conditions":"Recurrent Prostate Cancer","enrollment":36},{"nctId":"NCT01420250","phase":"PHASE1","title":"Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-09-22","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT02918968","phase":"PHASE4","title":"Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11-02","conditions":"Prostate Cancer","enrollment":206},{"nctId":"NCT02799706","phase":"PHASE3","title":"Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-09-25","conditions":"Prostate Cancer","enrollment":885},{"nctId":"NCT05663892","phase":"PHASE4","title":"Drug-Drug Interaction Study in Trans Women Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maple Leaf Research","startDate":"2022-11-23","conditions":"Hiv, Transgenderism","enrollment":45},{"nctId":"NCT03358563","phase":"EARLY_PHASE1","title":"Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-17","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT05140512","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2021-02-04","conditions":"Prostate Cancer","enrollment":23},{"nctId":"NCT03458221","phase":"PHASE2, PHASE3","title":"Signal TrAnsduction Pathway Activity Analysis in OVarian cancER","status":"RECRUITING","sponsor":"Gynaecologisch Oncologisch Centrum Zuid","startDate":"2023-01-31","conditions":"Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer","enrollment":148},{"nctId":"NCT04563936","phase":"PHASE3","title":"Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2020-01-06","conditions":"Prostate Cancer","enrollment":290},{"nctId":"NCT03541928","phase":"PHASE2","title":"Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-08-02","conditions":"High-risk Prostate Cancer, Prostate Cancer","enrollment":60},{"nctId":"NCT04220398","phase":"NA","title":"Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-01-10","conditions":"Prostate Cancer, Chemotherapy Effect, Hormone Sensitive Prostate Cancer","enrollment":475},{"nctId":"NCT02085252","phase":"PHASE3","title":"A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-06-03","conditions":"Prostate Cancer","enrollment":116},{"nctId":"NCT00283803","phase":"PHASE2","title":"Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2002-03-12","conditions":"Prostate Cancer","enrollment":32},{"nctId":"NCT02353988","phase":"PHASE2","title":"AR-inhibitor Bicalutamide in Treating Patients With TNBC","status":"UNKNOWN","sponsor":"Jinling Hospital, China","startDate":"2015-01","conditions":"Breast Neoplasms","enrollment":60},{"nctId":"NCT00666666","phase":"PHASE2","title":"R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07","conditions":"Adenocarcinoma of the Prostate, Stage IV Prostate Cancer","enrollment":55},{"nctId":"NCT01531205","phase":"PHASE2","title":"Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":2},{"nctId":"NCT00512668","phase":"PHASE1","title":"Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer","enrollment":24},{"nctId":"NCT00841113","phase":"PHASE3","title":"Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Speciality European Pharma Limited","startDate":"1999-01","conditions":"Prostate Cancer","enrollment":177}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bicalutamide Oral Product","genericName":"Bicalutamide Oral Product","companyName":"Gynaecologisch Oncologisch Centrum Zuid","companyId":"gynaecologisch-oncologisch-centrum-zuid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bicalutamide is a nonsteroidal antiandrogen that inhibits the action of androgens. Used for Metastatic prostate cancer, Early stage prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}